Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP)

Summary

This study evaluates the safety and tolerability of the investigational drug EF-022 in the treatment of adult patients with Recurrent Respiratory Papillomatosis (RRP). Patients will be administered EF-022, either intramuscular or subcutaneous, for a period of 6 months. Preliminary effect of the drug on the disease will be evaluated by following the number and severity of the lesions in the respiratory tract and the effect on voice changes.

Timeline

Start

2016-09

Primary completion

2018-09

Completion

—

Drugs

Indications